Onakome Omorogbe
Primary Care · Yorktown, VANPI 1396349767
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations.
Across 40 payments — averaging $81.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$444
- Johnson & Johnson$268
- Novo Nordisk$253
- Kyowa Kirin, Inc.$245
- Axsome Therapeutics, Inc.$224
- Eisai Inc.$214
- plus $2K from 16 others
What the payments were for
- Food & beverage$3,246100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $444 |
| Johnson & Johnson | 3 | $268 |
| Novo Nordisk | 3 | $253 |
| Kyowa Kirin, Inc. | 2 | $245 |
| Axsome Therapeutics, Inc. | 2 | $224 |
| Eisai Inc. | 2 | $214 |
| Corium, LLC | 2 | $133 |
| SK Life Science, Inc. | 1 | $125 |
| Lundbeck LLC | 1 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $123 |
| Xeris Pharmaceuticals, Inc. | 1 | $122 |
| Mylan Specialty L.p. | 1 | $121 |
| Boehringer Ingelheim | 1 | $118 |
| Otsuka America Pharmaceutical, Inc. | 2 | $113 |
| AstraZeneca | 1 | $113 |
| Sage Therapeutics, LLC | 1 | $107 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $98 |
| Dexcom, Inc. | 1 | $90 |
| E.r. Squibb & Sons, L.L.C. | 1 | $89 |
| Spark Therapeutics, Inc. | 1 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,246 in reported general payments places this provider in the 85th percentile of 142 primary care providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Naltrexone Hcl | 12 | $142 |
| Clonidine Hcl | 11 | $3 |
Paid to pharmacies, not to this prescriber.
Other primary care in Yorktown
- Rebecca GrinsellRichmond$12K
- Jennifer CampbellNewport News$8K
- Tien MaAnnandale$7K
- Michael CogginAshland$7K
- Erin StewartFredericksburg$6K
- Lawanda WoodNorfolk$6K
- Sara WeaverDanville$5K
- Luis Rivera PenaFalls Church$4K
- Erika RobinsonFredericksburg$4K
- Haley SwansonVirginia Beach$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.